Clozapine Treatment of Childhood-Onset Schizophrenia: Evaluation of Effectiveness, Adverse Effects, and Long-Term Outcome
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Objective Clozapine is a unique atypical antipsychotic with superior efficacy in treatment-resistant schizophrenia. Plasma concentration of clozapine and its major metabolite N-desmethylclozapine (NDMC) as well as the ratio of NDMC to clozapine have been reported to be predictors of clozapine response. Here we evaluate these as well as other measures in an effort to find predictors of response to clozapine in our early-onset treatment-refractory population. Method Fifty-four children and adolescents participated in double-blind (n = 22) or open-label (n = 32) clozapine trials. Clinical evaluations took place at baseline, week 6 on clozapine, and at 2- to 6-year follow-up. The data were analyzed in relation to demographics, age at onset, IQ, clozapine dose, and plasma concentrations of prolactin, clozapine, NDMC, and NDMC/clozapine ratio. Stepwise regression and correlation analyses were performed to find predictors of treatment response. Results Clinical improvement after 6 weeks of clozapine treatment, as measured by the percentage of improvement on the Brief Psychiatric Rating Scale and the Scale for the Assessment of Positive Symptoms, was strongly associated with the NDMC/clozapine ratio at the 6-week time point (Pearson correlation coefficient: r = 0.41; p Conclusions The NDMC/clozapine ratio may be a valuable predictor of response to clozapine and may suggest new approaches to clozapine treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the childhood schizophrenia studies, weight gain with clozapine appeared at a high rate, possibly higher than that of adult onset patients (48).”
From Pediatric psychopharmacology: Too much or too little? (2013) · cites this paper as [48]
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
(1976) · Medical Entomology and Zoology · Cited by 8,899
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,701
Scale for Assessment of Positive Symptoms (SAPS) 1984
Andreasen, N. C. (1995) · Open Scholarship Institutional Repository (Washington University in St. Louis) · Cited by 2,423
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Clozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Kapur, S., Zipursky, R. B., & Remington, G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 712
Research works printed but not linked: 1
- Perry, 1991, Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients, Am J Psychiatry, 148, 231
Cited by
Predictors of outcome in early-onset psychosis: a systematic review
Díaz-Caneja, C. M., Pina-Camacho, L., Rodríguez-Quiroga, A., Fraguas, D., Parellada, M., & Arango, C. (2015) · npj Schizophrenia · doi:10.1038/npjschz.2014.5 · Cited by 233
De Berardis, D., Rapini, G., Olivieri, L., Di Nicola, D., Tomasetti, C., Valchera, A., Fornaro, M., Di Fabio, F., Perna, G., Di Nicola, M., et al. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618756261 · Cited by 207
Schneider, C., Corrigall, R., Hayes, D., Kyriakopoulos, M., & Frangou, S. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.08.001 · Cited by 108
“After 6-8 weeks of CLZ treatment, there was an average improvement of 69% in the Brief Psychiatric Rating Scale (BPRS), which was the most commonly used outcome measure [16,26,41,43,27].”
BackgroundMethodInfluentialPharmacology of N-desmethylclozapine☆
Lameh, J., Burstein, E. S., TAYLOR, E., Weiner, D. M., Vanover, K. E., & BONHAUS, D. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.05.004 · Cited by 106
Singh, J. B., Robb, A. S., Vijapurkar, U., Nuamah, I. F., & Hough, D. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.06.021 · Cited by 101
Metadata
- Authors
- SPORN, A. L., VERMANI, A., GREENSTEIN, D. K., BOBB, A. J., SPENCER, E. P., CLASEN, L. S., TOSSELL, J. W., STAYER, C. C., GOCHMAN, P. A., LENANE, M. C., RAPOPORT, J. L., & GOGTAY, N.
- Affiliations
- Guy's Hospital (GB)
- Corresponding author
- SPORN, ALEXANDRA L.
- ORCID
- GOCHMAN, PETER A.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-10
- Volume
- 46
- Issue
- 10
- Pages
- 1349-1356
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W1966602005
- Cited by
- 107
- References
- 53
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 4 · 2019: 2 · 2018: 5 · 2017: 4 · 2016: 4 · 2015: 4 · 2014: 3 · 2013: 10 · 2012: 8
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- clozapine, childhood schizophrenia, treatment-resistant schizophrenia, N-desmethylclozapine, predictors of treatment response, plasma drug concentration, adverse effects, long-term outcomes, atypical antipsychotics, children and adolescents
- MeSH terms
- Adolescent, Child, Clozapine, Double-Blind Method, Drug Therapy, Female, Humans, Male, Brief Psychiatric Rating Scale, Schizophrenia, Childhood, Time Factors, Antipsychotic Agents, Treatment Outcome, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clozapine Treatment of Childhood-Onset Schizophrenia: Evaluation of Effectiveness, Adverse Effects, and Long-Term Outcome. https://app.cochat.ai/papers/10.1097/chi.0b013e31812eed10
- The paper
- SPORN, A. L., VERMANI, A., GREENSTEIN, D. K., BOBB, A. J., SPENCER, E. P., CLASEN, L. S., TOSSELL, J. W., STAYER, C. C., GOCHMAN, P. A., LENANE, M. C., RAPOPORT, J. L., & GOGTAY, N. (2007). Clozapine Treatment of Childhood-Onset Schizophrenia: Evaluation of Effectiveness, Adverse Effects, and Long-Term Outcome. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1097/chi.0b013e31812eed10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.